Chapter 8 Endogenous Opioids in the Etiology and Treatment of Multiple Sclerosis

In Multiple Sclerosis: Perspectives in Treatment and Pathogenesis [Internet]
27 November 2017
https://www.ncbi.nlm.nih.gov/books/NBK470156/

Serum [Met 5]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone

Exp Biol Med (Maywood)
September 2017
https://pubmed.ncbi.nlm.nih.gov/28766982/

Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization

Medical Sciences
21 September 2018
https://pdfs.semanticscholar.org/c495/7df14b181c4ae963a80fdeaf38c5cbb1a9e3.pdf?_ga=2.217655315.460139797.1583212532-762170649.1583212532

Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis

Brain Res
24 March 2011
https://www.ncbi.nlm.nih.gov/pubmed/21256121

A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis

J Mult Scler
September 2008
https://www.ncbi.nlm.nih.gov/pubmed/18728058

Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis

Exp Biol Med (Maywood)
November 2009
https://pubmed.ncbi.nlm.nih.gov/19855075/

Research on low dosage naltrexone

Tidsskr Nor Laegeforen
01 July 2011
https://tidsskriftet.no/2011/07/brev-til-redaktoren/forskning-pa-lavdosert-naltrekson

Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis

Mult Scler J Exp Transl Clin
29 September 2016
https://journals.sagepub.com/doi/full/10.1177/2055217316672242

Introduction: A retrospective study was conducted on patients at Penn State Hershey Medical Center diagnosed with relapsing–remitting multiple sclerosis between 2006 and 2015.

Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis

Ann Neurol
August 2010
https://pubmed.ncbi.nlm.nih.gov/20695007/

Objective: To evaluate the efficacy of 4.5mg nightly naltrexone on the quality of life of multiple sclerosis (MS) patients.

Bernard Bihari, MD: Low-Dose Naltrexone for normalizing immune system function

Altern Ther Health Med
05 November 2013
http://todayspractitioner.com/wp-content/uploads/2013/10/Bernard-Bihari-MD-Low-dose-Naltrexone-for-Normalizing-Immune-System-Function-athm_19_2_bihari_56_65.pdf